Skip to main content
Clinical Trials/NCT03614507
NCT03614507
Terminated
Not Applicable

Automation Oxygen Flow Titration in Spontaneously Breathing Infants Less Than One Year of Age During a First Episode of Bronchiolitis

University Hospital, Brest10 sites in 1 country105 target enrollmentOctober 9, 2018
ConditionsBronchiolitis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchiolitis
Sponsor
University Hospital, Brest
Enrollment
105
Locations
10
Primary Endpoint
Length of hospital stay in hours since the admission to the emergency room.
Status
Terminated
Last Updated
last year

Overview

Brief Summary

The objective of this study is to assess the efficacy of the FreeO2 device in shortening the hospital length of stay during a first episode of hypoxemic bronchiolitis in infants less than 1 year of age.

FreeO2Bronchio study is a multicenter, prospective, controlled, randomized, open-label study.

Detailed Description

This is a controlled, randomized, open-label, multicentre trial. Patients will be included after written informed consent will be obtained from the patients' parents or legally authorized representatives. Patients will be randomized either in the "FreeO2" group for automatic oxygen flow titration or in the "manual" group for Oxygen therapy with manual flow titration. The SpO2 will be recorded continuously in both groups of the study using the FreeO2 device throughout the duration of hospitalization; In the group "FreeO2 ", the device will record the data continuously and allow the automation of oxygen titration - in the group "Manual", the device will only be used to monitor SpO2 and heart rate.

Registry
clinicaltrials.gov
Start Date
October 9, 2018
End Date
July 5, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Infants from 1 month of age and less than 1 year of age who present a first episode of bronchiolitis and require oxygen therapy
  • Informed consent of parents (written informed consent will be obtained from the patients' parents or legally authorized representatives)
  • Affiliation to the French social security system

Exclusion Criteria

  • Need for oxygen flow higher than 3 L / min to maintain SpO2 greater than 92%
  • Patient with severity criteria according to the 2019 French National Authority for Health (HAS) guidelines and for whom it's indicated to maintain SpO2 above 94%
  • Criteria of severity justifying from the start another technique of assisted ventilation:
  • Polypnea: respiratory rate (FR)\> 80 c / min.
  • Consciousness with glasgow score (GSC) \<or =
  • Hemodynamic instability (mean arterial pressure (MAP) \<- 2 SD for age or use of vasopressors).
  • Cardiac or respiratory arrest.
  • PCO2\> 55 mm Hg and pH \<7.20 when blood gas are performed
  • Need for urgent surgery
  • Contraindication to the FreeO2 device as described in the user manual

Outcomes

Primary Outcomes

Length of hospital stay in hours since the admission to the emergency room.

Time Frame: 30 days max

The length of hospital stay in hours since admission in the emergency room will be compared between the two groups.

Secondary Outcomes

  • Number of patients readmited to hospital within 7 days and 30 days following discharge(30 days max)
  • Duration of enteral feeding (hours)(30 days max)
  • Duration of intravenous hydration (hours)(30 days max)
  • Number of patient admitted to the intensive care unit within 3 days following the hospital admission(30 days max)
  • Number of patients needing Heated Humidified High Flow Nasal Cannula (HFNNC)(30 days max)
  • Number of patients needing assisted ventilation (invasive or noninvasive )(30 days max)
  • Number of reported Adverse Events(30 days max)
  • Time spent in the a area of severe desaturation (SpO2 <92%) and of hyperoxia area (SpO2> 98%).(30 days max)

Study Sites (10)

Loading locations...

Similar Trials